GO
Loading...

Life Sciences

More

  • LONDON, April 2- GlaxoSmithKline Plc has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit.

  • April 1- France's Stallergenes said on Tuesday it received the U.S. Food and Drug Administration's green light to sell its immunotherapy pill Oralair for treating grass allergies. Oralair was approved in the European Union in 2008 and is also sold in Canada, Australia and Russia for the treatment of grass pollen allergy.

  • March 31- Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. Curis acquired the license to develop and market the treatment from Genentech, a unit of the Roche Holding AG, for an upfront payment of $9.5 million in November 2012.

  • March 27- Baxter International Inc said it would spin off its biotechnology operations into a publicly traded company by the middle of next year, leaving behind its core medical technology business.

  • *Sanofi hopes to deliver first doses in late 2015. *Sanofi has spent over 1.3 bln euros on project.

  • *Novartis reviewing fate of animal health, vaccines and OTC units. BASEL, Switzerland, March 20- Novartis Chief Executive Joe Jimenez is taking a hard look at the drugmaker's smaller businesses as he reshapes the company for what he expects to be a "brutal" new era in healthcare spending.

  • *MAGE-A3 fails to hit goal in Phase III lung cancer trial. March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British company said it still hoped to identify a sub-group of patients in which it would work.

  • March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British group said it still hoped to find a sub-group of patients in which it would work.

  • March 18- Shares of Galena Biopharma Inc fell as much as 21 percent on Tuesday after the company said the U.S. Securities and Exchange Commission was investigating its dealings with an external investor-relations firm.

  • Rivals race to develop new biotech asthma drugs Tuesday, 18 Mar 2014 | 8:48 AM ET

    *Rivals include Roche, AstraZeneca, Sanofi and Teva. LONDON, March 18- Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion.

  • March 14- An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.

  • March 10- Germany has granted Northwest Biotherapeutics Inc special permission to sell its experimental brain cancer drug in the country, the company said, and its stock jumped as much as 36 percent.

  • March 10- German health regulators have granted Northwest Biotherapeutics Inc special permission to sell its experimental brain cancer drug, DCVax-L, in the country, even though the small U.S. biotechnology company has not yet completed its late-stage trial of the immunotherapy.

  • Gene therapy may offer "functional" cure for HIV Wednesday, 5 Mar 2014 | 5:00 PM ET

    Data from the small study of the Sangamo BioSciences therapy, known by the code name SB-728-T, were issued in the New England Journal of Medicine, the first publication of data from a human trial of a technology called "gene editing." The Phase 1 trial, led by the University of Pennsylvania, enrolled 12 HIV patients.

  • Feb 19- Onconova Therapeutics Inc said its experimental blood disorder drug did not meet the main goal of a late-stage trial, sending its shares down 45 percent in extended trading. Since then the company's shares have fallen a little more than 15 percent and closed at $13.86 on Wednesday. The stock was trading at $8.35 in extended trading.

  • Feb 4- The U.S. Food and Drug Administration rejected a migraine drug made by Israel's RedHill Biopharma Ltd and Canada's IntelGenx Corp.. The FDA raised questions about the third-party manufacturing process, as well as the packaging and labeling of the drug, called RHB-103, the companies said in a statement.

  • *Ablynx initially to get 20 mln euros, plus 10.7 mln for research. *Ablynx shares gain up to 6.9 pct. BRUSSELS, Feb 3- Belgian biotech company Ablynx has signed a deal with Merck& Co worth up to 1.7 billion euros to develop ways of triggering the body to fight cancer by itself.

  • *Follows quality issue with some batches made in Belgium. FRANKFURT/ LONDON, Jan 28- GlaxoSmithKline has stopped worldwide deliveries of two chickenpox vaccines for children after discovering that some batches produced at its factory in Wavre, Belgium, were not up to standard.

  • COPENHAGEN, Jan 14- Danish biotech company Genmab has entered into a research collaboration with U.S. pharmaceutical company Eli Lilly involving its DuoBody technology platform.

  • AstraZeneca sees 2017 revenue in line with 2013 level Tuesday, 14 Jan 2014 | 2:15 AM ET

    LONDON, Jan 14- AstraZeneca said on Tuesday it expected to return to growth after a wave of drug patent expiries earlier than analysts currently forecast, with 2017 revenue likely to be broadly in line with the 2013 level.

Most Popular Video

Thursday, 17 Apr 2014 | 2:10 AM ET

Bill McDermott, co-CEO of SAP, says cloud computing is "growing faster than everything else" in the company.

Thursday, 17 Apr 2014 | 1:50 AM ET

Edward George, head of soft commodities at Ecobank, says chocolate will become a luxury in Europe as cocoa prices shoot up.

Wednesday, 16 Apr 2014 | 11:31 PM ET

Vera Eve Lim, CFO at Bank Danamon Indonesia, explains why the lender saw a 13 percent drop in first-quarter earnings.